Trial
NCT01302938
Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects With Overactive Bladder
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Collaborators
—
Condition
Overactive Bladder
Intervention
Tolterodine ER
Why stopped
Stop date for randomization: 31/5/2012. Recruitment terminated due to lack of recruitment. No new safety issues were identified.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-01-28